Corbus Pharmaceuticals Completes Enrollment in 240-Patient 20/40/60mg Phase 1b Obesity Trial
Corbus Pharmaceuticals has enrolled all 240 non-diabetic obese participants in its 16-week, dose-ranging CANYON-1 Phase 1b trial of CRB-913, with dosing cohorts at 20mg, 40mg and 60mg daily and completion expected summer 2026. Earlier Phase 1a results showed a mean 2.9% placebo-adjusted weight loss at Day 14 with a favorable GI and neuropsychiatric safety profile.
1. Phase 1b Enrollment Completed
Corbus has enrolled the last patient first visit in its CANYON-1 Phase 1b trial, marking full enrollment of 240 obese, non-diabetic participants in a 16-week, double-blind, placebo-controlled, dose-ranging study.
2. CANYON-1 Trial Design
Participants start at 20mg daily oral dosing of CRB-913 and titrate up to either 40mg or 60mg, with three months of dosing followed by one month of safety follow-up, targeting completion in summer 2026.
3. Phase 1a Efficacy and Safety
In the Phase 1a SAD and MAD study, obese subjects receiving up to 150mg/day experienced a mean 2.9% placebo-adjusted weight loss by Day 14, with no reports of vomiting, constipation, nausea or neuropsychiatric adverse events.
4. Next Milestones
The upcoming Phase 1b data readout will assess CRB-913's potential as a novel oral CB1 inverse agonist for weight loss and long-term weight management, offering an alternative to incretin therapies.